Erdosteine (Elmucin) 300 mg – [10 capsules]

The effectiveness of Erdostein is due to the action of active metabolites. Thiol groups of metabolites cause rupture of disulfide bridges, which bind glycoprotein fibers to one another, resulting in reduction of elasticity and viscosity of sputum. As a result, erdosteine enhances and accelerates release of secretion from respiratory tract, improves secretory function of epithelium and increases efficiency of mucociliary transport in upper and lower parts of respiratory tract. Erdostein has an antioxidant effect and transfers free radicals. In particular, erdostein protects the respiratory tract from the damaging effects of cigarette smoke with respect to the inactivation of alpha-1-antitrypsin.

Erdostein increases the concentration of immunoglobulin A (IgA) in airway mucosa in patients with chronic obstructive airway disease and also reduces the suppressive effect of tobacco smoke on granulocyte function.

The effect of Erdostein therapy develops on the 3rd-4th day of treatment. Erdosteine as such does not contain free SH-radicals, so it has no damaging effect on the gastrointestinal tract, and the side effects on the digestive system do not differ from the placebo effects.

Respiratory diseases with formation of viscous sputum (in complex therapy).

Contraindications .

Hypersensitivity to the components that make up the drug.

Childhood age under 18 years.

Liver function impairment.

Renal failure.

Homocystinuria (the drug is a source of homocysteine, so amino acid metabolism disorders are possible in patients on diets with low free methionine content).

Pregnancy (first trimester).

Breast-feeding period.

Caution.

Caution should be exercised when using the drug in patients with severe liver dysfunction and in case of bronchial diseases associated with excessive secretion.

Administration during pregnancy and lactation

Preclinical studies have not revealed an embryotoxic effect of Erdosteine. The experience of using Erdosteine in pregnancy and during breastfeeding is limited. Therefore, administration of Erdosteine (Elmucin) is possible only by physician’s prescription in II and III trimesters of pregnancy, if the expected benefits to the mother exceed the potential risk to the fetus.

1 capsule (300 mg) 2 times a day.

If there is no improvement within 5 days after initiation of the drug or if deterioration occurs, consult the attending physician.